In the BioHarmony Drug Report Database

"Preview" Icon

Pemigatinib

Pemazyre (pemigatinib) is a small molecule pharmaceutical. Pemigatinib was first approved as Pemazyre on 2020-04-17. It is used to treat cholangiocarcinoma in the USA. It has been approved in Europe to treat cholangiocarcinoma. The pharmaceutical is active against fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, and fibroblast growth factor receptor 2. Pemazyre’s patents are valid until 2035-01-30 (FDA).

 

Trade Name

 

Pemazyre
 

Common Name

 

pemigatinib
 

ChEMBL ID

 

CHEMBL4297522
 

Indication

 

cholangiocarcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Pemigatinib structure rendering